All manuscripts
Publications VST Cells G-Rex®24 Well Plate

Virus Induced Lymphocytes (VIL) as a novel viral antigen‑specific T cell therapy for COVID‑19 and potential future pandemics

Published Journal Scientific Reports

Share
15 pages Virus Induced Lymphocytes (VIL) as a novel viral antigen‑specific T cell therapy for COVID‑19 and potential future pandemics — Scientific Reports, 2021

Overview

The authors developed Virus Induced Lymphocytes (VIL) for COVID-19 using artificial APCs (VIPR particles). G-Rex® plates were used to facilitate rapid expansion (7 days) of SARS-CoV-2 specific T cells. The resulting VILs showed a polyfunctional cytokine profile and effector memory phenotype.

What this paper found

Bead-based artificial antigen-presenting cells (VIPR particles) carrying a SARS-CoV-2 Spike peptide-MHC pentamer and anti-CD28 antibodies expanded virus-specific CD8+ T cells from convalescent COVID-19 donors more than 1000-fold on average within 7 days. T cells were cultured with one particle per 20 T cells in medium with 6000 IU/ml IL-2, IL-7, IL-15 and N-acetylcysteine, in G-Rex® 24-well plates. Cultures seeded with 1 × 10^6 T cells reached 2.6 to 4.5 × 10^7 cells by day 7, with an average of 2.4 × 10^5 SARS-CoV-2-specific CD8+ T cells per million T cells cultured. CMV-specific CD8+ T cells expanded on average more than 700-fold. Expanded virus-specific cells showed an effector memory phenotype and produced IFN-γ, TNFα and IL-2 on peptide restimulation.

Note: Ex vivo study using T cells from convalescent donors; the authors note that whether the expanded cells provide lasting immunological memory still requires in vivo assessment in a viral infection setting.

Our approach enables an over 1000-fold expansion in the numbers of viral antigen-specific T cells in just 7-days from isolation of a patient’s T cells, providing a higher quantity of activated, polyfunctional effector memory cells. — Rohan Sivapalan, Jinyan Liu, Krishnendu Chakraborty, Elisa Arthofer, Modassir Choudhry, Philip S. Barie, Dan H. Barouch, Tom Henley, Scientific Reports

Study details

Authors
Rohan Sivapalan, Jinyan Liu, Krishnendu Chakraborty, Elisa Arthofer, Modassir Choudhry, Philip S. Barie, Dan H. Barouch, Tom Henley
Institution
Intima Bioscience, Inc., New York, NY, USA · Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA · Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA · Division of Trauma, Burns, Acute and Critical Care, Department of Surgery, and Division of Medical Ethics, Department of Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA
Journal
Scientific Reports
Year
2021
PMID / PMC
PMID: 34315945 · PMC
G-Rex® model(s)
G-Rex®24 Well Plate
Cell type(s)
VST Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

Isolated CD3+ T cells were seeded at 1-2 × 10^6 cells per cm² in G-Rex® 24-well plates (Wilson-Wolf) with VIPR particles at 20 T cells per particle and cultured for 7 days in medium with 6000 IU/ml IL-2, IL-7, IL-15 and N-acetylcysteine. In some experiments the G-Rex® medium was left unchanged for the full 7 days to promote expansion. Cultures seeded with 1 × 10^6 T cells reached on average 2.6 to 4.5 × 10^7 cells at day 7.

Explore related

Full citation

Sivapalan R, Liu J, Chakraborty K, et al. Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. Sci Rep. 2021;11(1):15295.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →